Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 10 versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 10 versus TRAVASOL 2 75 IN DEXTROSE 20 IN PLASTIC CONTAINER.
AMINOSYN 10% vs TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 10% provides a mixture of essential and non-essential amino acids to support protein synthesis and maintain nitrogen balance in patients unable to tolerate adequate oral or enteral nutrition. Each amino acid serves as a substrate for protein synthesis, hormone production, and other metabolic processes.
Provides exogenous amino acids and dextrose to meet caloric and protein requirements in patients who cannot tolerate enteral nutrition. Amino acids are used for protein synthesis and as substrates for gluconeogenesis and other metabolic pathways.
Intravenous infusion: 1-1.5 g/kg/day (as amino acids), typically 500 mL of 10% solution (50 g amino acids) over 8-12 hours daily.
Intravenous infusion: 500 mL to 1000 mL over 24 hours, titrated to provide 2.75% amino acids and 20% dextrose as part of parenteral nutrition. Rate based on glucose tolerance and metabolic needs.
None Documented
None Documented
Amino acids: 0.5-1 hour for free amino acids; terminal half-life of infused nitrogen is approximately 2-4 hours; clinical context: reflects rapid uptake and metabolism.
Amino acids: not applicable (endogenous metabolites). Dextrose: <15 minutes; clinical context: continuous infusion required to maintain glucose homeostasis.
Renal (primarily as amino acids and metabolites); ~90% of infused amino nitrogen is excreted renally within 24-48 hours; <5% biliary/fecal.
Amino acids and dextrose are metabolized; excess nitrogen is excreted primarily as urea in urine. Dextrose is metabolized to CO2 and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution